References
- Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl. Acad Sci USA 2011;108:E586–94
- Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016;34:1097–103
- Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, et al. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 2005;102:17342–7
- Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Thermodynamic instability of human lambda 6 light chains: Correlation with fibrillogenicity. Biochemistry 1999;38:14101–8
- Wall JS, Martin EB, Richey T, Stuckey AC, Macy S, Wooliver C, Williams A, et al. Preclinical validation of the heparin-reactive peptide p5 + 14 as a molecular imaging agent for visceral amyloidosis. Molecules 2015;20:7657–82